Search company, investor...

Inna Pharma

Founded Year

2019

Stage

Seed VC | Alive

Total Raised

$5.94M

Last Raised

$5.94M | 2 mos ago

About Inna Pharma

Inna Pharma is an original pharmaceutical company focusing on a small molecule MyD88 inhibitor, for the treatment of extensive and serious major immune disorders. The company was founded in 2019 and is based in Ningbo, China.

Headquarters Location

8-4-1, Building 1, East District, Ningbo New Material Innovation Center

Ningbo, Zhejiang ,

China

Missing: Inna Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Inna Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Inna Pharma Frequently Asked Questions (FAQ)

  • When was Inna Pharma founded?

    Inna Pharma was founded in 2019.

  • Where is Inna Pharma's headquarters?

    Inna Pharma's headquarters is located at 8-4-1, Building 1, East District, Ningbo New Material Innovation Center, Ningbo.

  • What is Inna Pharma's latest funding round?

    Inna Pharma's latest funding round is Seed VC.

  • How much did Inna Pharma raise?

    Inna Pharma raised a total of $5.94M.

  • Who are the investors of Inna Pharma?

    Investors of Inna Pharma include Zhongbo Capital, Zhuhai Hi-Tech Venture Capital and Huajin Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.